Next Article in Journal
Functional Link between miR-200a and ELK3 Regulates the Metastatic Nature of Breast Cancer
Next Article in Special Issue
Merkel Cell Polyomavirus and Merkel Cell Carcinoma
Previous Article in Journal
Treatment of Smoldering Multiple Myeloma: Ready for Prime Time?
Previous Article in Special Issue
Artesunate Affects T Antigen Expression and Survival of Virus-Positive Merkel Cell Carcinoma
Article

Merkel Cell Carcinoma Treatment in Finland in 1986–2016—A Real-World Data Study

by 1,*,†, 2,†, 3,4 and 2
1
Department of Dermatology, Allergology and Venerology, HUS Inflammation Center, University of Helsinki and Helsinki University Hospital, P.O. Box 160, FIN-00029 HUS Helsinki, Finland
2
Department of Plastic Surgery, University of Helsinki and Helsinki University Hospital, FIN-00029 HUS Helsinki, Finland
3
Finnish Institute for Health and Welfare, FIN-00271 Helsinki, Finland
4
Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, 171 65 Solna, Stockholm, Sweden
*
Author to whom correspondence should be addressed.
These authors contributed equally and share first authorship.
Cancers 2020, 12(5), 1224; https://doi.org/10.3390/cancers12051224
Received: 20 March 2020 / Revised: 25 April 2020 / Accepted: 6 May 2020 / Published: 13 May 2020
(This article belongs to the Special Issue The Biological and Clinical Aspects of Merkel Cell Carcinoma)
Merkel cell carcinoma (MCC) is a rare cutaneous carcinoma that has gained enormous interest since the discovery of Merkel cell polyoma virus, which is a causative oncogenic agent in the majority of MCC tumours. Increased research has focused on effective treatment options with immuno-oncology. In this study, we reviewed the real-world data on different treatments given to MCC patients in Finland in 1986–2016. We used the Finnish Cancer Registry database to find MCC patients and the Hospital Discharge Register and the Cause-of-Death Register to obtain treatment data. We identified 376 MCC patients and 33 different treatment entities and/or combinations of treatment. An increase was noted in the incidence of MCC since 2005. Therefore, the cohort was divided into two groups: the “early“ group with time of diagnosis between years 1986 and 2004 and the “late” group with time of diagnosis between 2005 and 2016. The multitude of different treatment combinations is a relatively new phenomenon; before the year 2005, only 11 treatments or treatment combinations were used for MCC patients. Our data show that combining radiation therapy with simple excision provided a survival advantage, which was, however, lost after adjustment for stage or age. Our registry study serves as a baseline treatment efficacy comparison as we move into the age of immunotherapy in MCC. Standardizing the treatment of MCC patients in Finland requires more work on awareness and multidisciplinary co-operation. View Full-Text
Keywords: Merkel cell carcinoma; treatment; radiation therapy; immunotherapy; surgical intervention; survival; multidisciplinary communication Merkel cell carcinoma; treatment; radiation therapy; immunotherapy; surgical intervention; survival; multidisciplinary communication
Show Figures

Figure 1

MDPI and ACS Style

Sahi, H.; Their, J.; Gissler, M.; Koljonen, V. Merkel Cell Carcinoma Treatment in Finland in 1986–2016—A Real-World Data Study. Cancers 2020, 12, 1224. https://doi.org/10.3390/cancers12051224

AMA Style

Sahi H, Their J, Gissler M, Koljonen V. Merkel Cell Carcinoma Treatment in Finland in 1986–2016—A Real-World Data Study. Cancers. 2020; 12(5):1224. https://doi.org/10.3390/cancers12051224

Chicago/Turabian Style

Sahi, Helka, Jenny Their, Mika Gissler, and Virve Koljonen. 2020. "Merkel Cell Carcinoma Treatment in Finland in 1986–2016—A Real-World Data Study" Cancers 12, no. 5: 1224. https://doi.org/10.3390/cancers12051224

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop